Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy - PubMed (original) (raw)
. 2000 Mar 2;19(10):1245-56.
doi: 10.1038/sj.onc.1203434.
Affiliations
- PMID: 10713666
- DOI: 10.1038/sj.onc.1203434
Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy
A N Bullock et al. Oncogene. 2000.
Abstract
The tumour suppressor p53 is mutated in half of all human cancers, most frequently with missense substitutions in its core domain. We present a new assessment of the mutation database based on quantitative folding and DNA-binding studies of the isolated core domain. Our data identify five distinct mutant classes that correlate with four well-defined regions of the core domain structure. On extrapolation to 37 degrees C the wild-type protein has a stability of 3.0 kcal/mol. This also emerges as an oncogenic threshold: all beta-sandwich mutants destabilized by this amount (50% denatured) are expected to promote cancer. Other weakly destabilizing mutations are restricted to loop 3 in the DNA-binding region. Drugs that stabilize mutant p53 folding have the potential to reactivate apoptotic signalling pathways in tumour cells either by transactivation-dependent or independent pathways. Using an affinity ligand as a proof of principle we have recovered the thermodynamic stability of the hotspot G245S. With reference states for the five mutant classes as a guide, future therapeutic strategies may similarly stabilize partially structured or binding states of mutant p53 that restore limited p53 pathways to tumour suppression.
Similar articles
- Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O, Rozenberg H, Brosh R, Diskin-Posner Y, Kessler N, Shimon LJ, Frolow F, Liran A, Rotter V, Shakked Z. Suad O, et al. J Mol Biol. 2009 Jan 9;385(1):249-65. doi: 10.1016/j.jmb.2008.10.063. Epub 2008 Oct 30. J Mol Biol. 2009. PMID: 18996393 - Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
Selivanova G, Wiman KG. Selivanova G, et al. Oncogene. 2007 Apr 2;26(15):2243-54. doi: 10.1038/sj.onc.1210295. Oncogene. 2007. PMID: 17401433 Review. - Characterization of the p53-rescue drug CP-31398 in vitro and in living cells.
Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht AR. Rippin TM, et al. Oncogene. 2002 Mar 28;21(14):2119-29. doi: 10.1038/sj.onc.1205362. Oncogene. 2002. PMID: 11948395 - Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal A, Rotter V. Sigal A, et al. Cancer Res. 2000 Dec 15;60(24):6788-93. Cancer Res. 2000. PMID: 11156366 Review. - Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function.
Lubin DJ, Butler JS, Loh SN. Lubin DJ, et al. J Mol Biol. 2010 Jan 29;395(4):705-16. doi: 10.1016/j.jmb.2009.11.013. Epub 2009 Nov 11. J Mol Biol. 2010. PMID: 19913028
Cited by
- The tumor suppressor p53: from structures to drug discovery.
Joerger AC, Fersht AR. Joerger AC, et al. Cold Spring Harb Perspect Biol. 2010 Jun;2(6):a000919. doi: 10.1101/cshperspect.a000919. Epub 2010 Feb 10. Cold Spring Harb Perspect Biol. 2010. PMID: 20516128 Free PMC article. Review. - BAG2 drives chemoresistance of breast cancer by exacerbating mutant p53 aggregate.
Huang X, Shi D, Zou X, Wu X, Huang S, Kong L, Yang M, Xiao Y, Chen B, Chen X, Ouyang Y, Song L, Jian Y, Lin C. Huang X, et al. Theranostics. 2023 Jan 1;13(1):339-354. doi: 10.7150/thno.78492. eCollection 2023. Theranostics. 2023. PMID: 36593950 Free PMC article. - Stability of the core domain of p53: insights from computer simulations.
Madhumalar A, Smith DJ, Verma C. Madhumalar A, et al. BMC Bioinformatics. 2008;9 Suppl 1(Suppl 1):S17. doi: 10.1186/1471-2105-9-S1-S17. BMC Bioinformatics. 2008. PMID: 18315848 Free PMC article. - Follow the Mutations: Toward Class-Specific, Small-Molecule Reactivation of p53.
Loh SN. Loh SN. Biomolecules. 2020 Feb 14;10(2):303. doi: 10.3390/biom10020303. Biomolecules. 2020. PMID: 32075132 Free PMC article. Review. - Structure-based predictions broadly link transcription factor mutations to gene expression changes in cancers.
Ashworth J, Bernard B, Reynolds S, Plaisier CL, Shmulevich I, Baliga NS. Ashworth J, et al. Nucleic Acids Res. 2014 Dec 1;42(21):12973-83. doi: 10.1093/nar/gku1031. Epub 2014 Nov 5. Nucleic Acids Res. 2014. PMID: 25378323 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous